Enspryng (satralizumab-mwge) Patient Assistance Program
Don’t let the high cost of brand anti-IL-6 receptor antibody disrupt your AQP4-IgG-positive neuromyelitis optica spectrum disorder care. We help eligible patients access Enspryng (satralizumab-mwge subcutaneous injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Enspryng (satralizumab-mwge) is FDA-approved for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. Humanized anti-IL-6 receptor recycling monoclonal antibody — the first FDA-approved IL-6R blocker for NMOSD. Convenient monthly SC self-injection at home after initial loading.
- Without assistance, Enspryng costs commonly run approximately $14,000–$18,000 per dose (monthly after loading).
- Through AffordMyPrescriptions, qualifying patients can access Enspryng for a flat $69.95 per month.
- Other AQP4-IgG-positive NMOSD therapies: eculizumab (Soliris — anti-C5), ravulizumab (Ultomiris — long-acting anti-C5, every 8 weeks), inebilizumab (Uplizna — anti-CD19 B-cell depletion every 6 months). Off-label/historical immunosuppression: rituximab biosimilars, mycophenolate mofetil (generic), azathioprine (generic). For acute attacks: high-dose IV methylprednisolone (generic), plasmapheresis, IVIG. NMOSD is distinct from multiple sclerosis — MS DMTs (e.g., Ocrevus, interferons) may worsen NMOSD. AQP4-IgG testing and proper diagnosis are essential before treatment selection.
What is Enspryng Prescription Assistance Program?
The Enspryng Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Enspryng (used for AQP4-IgG-positive neuromyelitis optica spectrum disorder in adults) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, neurology coordination, AQP4-IgG documentation, and ongoing renewal — which can be overwhelming when managing a rare relapsing neurologic disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Enspryng PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your neurologist for required documentation (typically including AQP4-IgG results, MRI imaging, attack history, and clinical criteria), follow up with the manufacturer’s program until approval, manage your monthly SC injection schedule, and handle annual re-certification.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Enspryng enrollment — from the initial application through ongoing refills and re-enrollment — so you never face a gap in your neuromyelitis optica spectrum disorder treatment.
Pharmacy Price Comparison
- Without assistance, Enspryng costs thousands of dollars per dose at specialty pharmacies. Discount cards offer minimal relief at this price point, but a Patient Assistance Program can make this NMOSD biologic accessible if you qualify. The table below compares typical pricing to what you'd pay with our Enspryng advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Uplizna (alt anti-CD19) | ~$80,000 every 6mo | Alt B-cell depletion |
| Walgreens | ~$17,000/dose | Save substantially |
| CVS Pharmacy | ~$18,000/dose | Save substantially |
| Walmart | ~$15,000/dose | Save substantially |
| Specialty pharmacy | ~$14,000/dose | Save substantially |
| Soliris/Ultomiris (alt) | ~$30,000/dose | Alt anti-C5 NMOSD therapy |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Enspryng — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Enspryng Prescription Program?
The Enspryng Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy. Enspryng’s monthly SC self-injection at home offers a significant convenience advantage for NMOSD patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Enspryng assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Enspryng is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Enspryng:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $14,000–$18,000/dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Enspryng assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Enspryng Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Enspryng:
Enspryng is a humanized anti-IL-6 receptor recycling monoclonal antibody — designed for extended half-life and convenient monthly SC dosing. IL-6 signaling drives autoreactive B-cell differentiation, T-cell helper function, and AQP4-IgG production in NMOSD. The SAkuraSky and SAkuraStar trials established efficacy in reducing NMOSD relapses.
How It Works:
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune CNS demyelinating disease characterized by severe optic neuritis and longitudinally extensive transverse myelitis. AQP4-IgG-positive NMOSD is driven by aquaporin-4 autoantibody binding to astrocytic AQP4 channels — activating complement and causing severe CNS damage. IL-6 signaling drives B-cell differentiation into AQP4-IgG-producing plasmablasts. Satralizumab binds the IL-6 receptor (membrane-bound and soluble), blocking IL-6 signaling. A recycling design (pH-dependent binding) extends the half-life, enabling monthly dosing. It significantly reduces NMOSD relapse frequency in clinical trials. Monthly SC self-injection at home after initial loading.
Form and Use:
Enspryng 120 mg/mL prefilled syringe (1 mL) SC injection. Loading: 120 mg SC at weeks 0, 2, and 4. Maintenance: 120 mg SC every 4 weeks. Self-administered at home after initial training. Rotate injection sites (abdomen, thigh, upper arm). Refrigerate; allow to reach room temperature 30 minutes before injection. Periodic CBC, liver enzymes, lipid panel, and infection monitoring.
Generic Availability:
No biosimilar/generic Enspryng. Other AQP4-IgG-positive NMOSD therapies: eculizumab (Soliris — anti-C5 complement inhibitor, every 2 weeks IV; biosimilars emerging), ravulizumab (Ultomiris — long-acting anti-C5, every 8 weeks IV after loading), inebilizumab (Uplizna — anti-CD19 B-cell depletion, every 6 months IV after loading). Off-label/historical immunosuppression: rituximab biosimilars (Truxima, Ruxience, Riabni), mycophenolate mofetil (CellCept — generic), azathioprine generic, methotrexate generic. For acute attacks: high-dose IV methylprednisolone (generic), plasma exchange, IVIG. Important: NMOSD is distinct from multiple sclerosis — MS DMTs (interferons, fingolimod, dimethyl fumarate, natalizumab, Ocrevus) may worsen NMOSD and should be avoided. AQP4-IgG testing and proper diagnosis are essential before treatment selection.
Warnings:
Serious infections (bacterial, viral, fungal — including hepatitis B reactivation; screen HBV; opportunistic infections), neutropenia and cytopenias (monitor CBC), hepatotoxicity (monitor LFTs — hold for severe), hyperlipidemia (monitor lipid panel), hypersensitivity reactions including anaphylaxis, gastrointestinal perforation (rare, increased with diverticulitis history), embryo-fetal toxicity. Other: injection site reactions, headache, fatigue, nausea, joint pain, dyspepsia. Live vaccines avoided. Update non-live vaccines (annual flu, pneumococcal, COVID-19, recombinant zoster, HBV) before starting if possible.
FAQ (Frequently Asked Questions)
How much does Enspryng cost without insurance?
$14,000–$18,000 per dose (monthly after initial loading). Annual cost can exceed $200,000. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this NMOSD therapy.
What is NMOSD and why is AQP4-IgG testing important?
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune CNS demyelinating disease — distinct from multiple sclerosis. Characteristic features include severe optic neuritis and longitudinally extensive transverse myelitis. AQP4-IgG-positive NMOSD is driven by autoantibodies against aquaporin-4. AQP4-IgG testing (cell-based assay preferred) confirms diagnosis and guides treatment. Enspryng is FDA-approved specifically for AQP4-IgG-positive patients.
Why are MS therapies dangerous for NMOSD patients?
MS DMTs (interferons, fingolimod, dimethyl fumarate, natalizumab, Ocrevus) can worsen NMOSD — causing severe attacks. Proper diagnostic distinction between MS and NMOSD is critical before initiating any DMT. AQP4-IgG testing in any suspected demyelinating disease is essential.
What is the difference between Enspryng and Soliris/Ultomiris for NMOSD?
Different mechanisms. Soliris and Ultomiris are anti-C5 complement inhibitors. Enspryng is anti-IL-6 receptor — blocking IL-6-driven B-cell differentiation and autoantibody production. Soliris is every 2 weeks IV; Ultomiris every 8 weeks IV after loading; Enspryng monthly SC at home. Choice often by patient preference, insurance, and clinical factors.
Why is hepatitis B screening required before Enspryng?
IL-6 inhibition and other immunomodulatory therapy can reactivate hepatitis B in patients with prior exposure. Screen HBsAg, anti-HBc, and anti-HBs before initiation. Antiviral prophylaxis with entecavir or tenofovir is appropriate if there is HBV exposure history. Active HBV is a contraindication.
Take Control of Your Medication Costs
Targeted anti-IL-6R biologic therapy for AQP4-IgG-positive neuromyelitis optica spectrum disorder should not be derailed by cost. Proper AQP4-IgG diagnosis is essential — NMOSD must be distinguished from MS to avoid harmful MS therapy. Our Enspryng advocacy team is ready to verify eligibility, complete the manufacturer application, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.